Euglycaemic Ketoacidosis Due to Extremely Low-Calorie Intake and Dehydration After Laparoscopic Sleeve Gastrectomy in a Patient with Type 2 Diabetes.

Liu Z, Xiao L, Jin C, Xiao J, Zhao W

Diabetes, metabolic syndrome and obesity : targets and therapy6 Aug 2022Cited by 3 (Europe PMC)

PMID35966831PMCIDPMC9365319DOI10.2147/dmso.s373712PepBankPUB-35966831

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome
After sleeve gastrectomy, a patient prescribed degludec insulin, metformin and dulaglutide had blood glucose below 13.9 mmol/L.
In plain wordsAfter surgery, a patient taking insulin, metformin and dulaglutide had blood sugar below the reported threshold.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBlood glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Measurements
Blood glucose
< 13.9 mmol/L
degludec insulin, metformin and dulaglutide
Source sentences
Summary
She was prescribed degludec insulin, metformin and dulaglutide and her blood sugar was lower than 13.9 mmol/L.
3 context sentences(design, population, supporting numbers)
Summary · context
A 35-year-old female patient was diagnosed with T2DM and obesity.
Summary · context
The patient underwent laparoscopic sleeve gastrectomy to lose weight and control her blood glucose levels.
Summary · context
Her daily fluid intake was 800-1000 mL, and her daily caloric intake was less than 500 kcal during the first days after the surgery.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3596683101
02HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome
A patient prescribed degludec insulin, metformin and dulaglutide reported fatigue after sleeve gastrectomy.
In plain wordsA patient taking insulin, metformin and dulaglutide reported fatigue after surgery.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableFatigue
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
On postoperative Day 6, the patient complained of fatigue and vomiting.
4 context sentences(design, population, supporting numbers)
Summary · context
A 35-year-old female patient was diagnosed with T2DM and obesity.
Summary · context
The patient underwent laparoscopic sleeve gastrectomy to lose weight and control her blood glucose levels.
Summary · context
Her daily fluid intake was 800-1000 mL, and her daily caloric intake was less than 500 kcal during the first days after the surgery.
Summary · context
She was prescribed degludec insulin, metformin and dulaglutide and her blood sugar was lower than 13.9 mmol/L.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3596683102
03HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome
A patient prescribed degludec insulin, metformin and dulaglutide reported vomiting after sleeve gastrectomy.
In plain wordsA patient taking insulin, metformin and dulaglutide reported vomiting after surgery.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVomiting
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
On postoperative Day 6, the patient complained of fatigue and vomiting.
4 context sentences(design, population, supporting numbers)
Summary · context
A 35-year-old female patient was diagnosed with T2DM and obesity.
Summary · context
The patient underwent laparoscopic sleeve gastrectomy to lose weight and control her blood glucose levels.
Summary · context
Her daily fluid intake was 800-1000 mL, and her daily caloric intake was less than 500 kcal during the first days after the surgery.
Summary · context
She was prescribed degludec insulin, metformin and dulaglutide and her blood sugar was lower than 13.9 mmol/L.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3596683103
04HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome
A patient prescribed degludec insulin, metformin and dulaglutide developed ketoacidosis after sleeve gastrectomy amid low intake and dehydration.
In plain wordsA patient taking insulin, metformin and dulaglutide developed ketoacidosis after surgery with low food and fluid intake.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableKetoacidosis
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Blood gas analysis and urine analysis supported the diagnosis of ketoacidosis.
5 context sentences(design, population, supporting numbers)
Summary · context
We report an extremely rare case of T2DM in which the patient developed EKA after laparoscopic sleeve gastrectomy owing to extremely low-calorie intake and dehydration.
Summary · context
A 35-year-old female patient was diagnosed with T2DM and obesity.
Summary · context
The patient underwent laparoscopic sleeve gastrectomy to lose weight and control her blood glucose levels.
Summary · context
Her daily fluid intake was 800-1000 mL, and her daily caloric intake was less than 500 kcal during the first days after the surgery.
Summary · context
She was prescribed degludec insulin, metformin and dulaglutide and her blood sugar was lower than 13.9 mmol/L.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3596683104
05HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome
The patient prescribed degludec insulin, metformin and dulaglutide recovered after fluid, insulin and glucose treatment for postoperative ketoacidosis.
In plain wordsThe patient recovered after fluids, insulin and glucose treated postoperative ketoacidosis.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableRecovery from ketoacidosis
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
On postoperative Day 8, the patient recovered without any symptoms.
5 context sentences(design, population, supporting numbers)
Summary · context
Fluid resuscitation, insulin and glucose were administered to the patient immediately.
Summary · context
A 35-year-old female patient was diagnosed with T2DM and obesity.
Summary · context
The patient underwent laparoscopic sleeve gastrectomy to lose weight and control her blood glucose levels.
Summary · context
Her daily fluid intake was 800-1000 mL, and her daily caloric intake was less than 500 kcal during the first days after the surgery.
Summary · context
She was prescribed degludec insulin, metformin and dulaglutide and her blood sugar was lower than 13.9 mmol/L.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3596683105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.